Fresenius Invests in BioIntellisense AI Platform
“We made this strategic investment in BioIntelliSense to enable our medical staff to more efficiently and effectively continuously monitor patients, facilitating precise and timely interventions and reducing cost to the system,” explains FMCNA CEO, Bill Valle.
Read the full article » | Posted 09-12-2019
Related Articles
- The National Kidney Foundation has Updated Two of its Home Dialysis Resources Posted 03-13-2025
- See How Outset Medical is Bringing Home HD into Skilled Nursing Facilities Posted 03-13-2025
- Monogram Health Held a Home Dialysis Summit for its Clinicians Posted 03-13-2025
- Annual Dialysis Conference 2025 is in Las Vegas from 3/13-16/2025 Posted 03-13-2025